Any current/future capex/capital investment/strategic investment?

The company plans to expand some healthcare capacities over the next 18 to 24 months, including doubling up on some pen platforms to meet growing demand. No significant additional investment is needed to switch capacities from existing non-healthcare segments to other areas like automotive; only marginal investment in testing equipment or robotic handling may be required. The existing drug device capacity is 40 million devices, and the company is targeting to utilize and expand this capacity within the next 18 to 24 months. Shaily UK’s profitability is expected to grow alongside Indian m

Future growth expectations in sales/revenue/volumes?

Healthcare segment expects strong volume growth, particularly from Q2 FY25 onwards, following resolution of Q1 technical issues. Anticipated revenue growth in Healthcare projected at 20%+ for FY25; consolidated growth driven by Healthcare expansion. New contracts and projects in Healthcare (e.g., Lanreotide, Semaglutide) expected to contribute revenues in coming quarters. Own IP insulin pen injector order for 10 million units per year indicates scaling opportunity; additional large insulin orders likely in next 1-2 years. UK business projected to grow 35-45%, with continued development

Future growth expectations in earnings/operating earnings/profits/EPS?

Shaily Engineering Plastics Limited delivered a robust 14% revenue growth in Q1 FY25 and improved EBITDA margins to 20.1%. The Healthcare segment revenue grew 21%, with strong order pipelines including new pen injectors and contract manufacturing opportunities. UK business expected to grow 35-45%, with profitability increasing alongside scale-up in India operations. Purchase orders for 10 million pen injectors for insulin market indicate significant volume growth potential. Anticipated doubling of pen platform capacities in the next 18-24 months to meet rising demand. Outlook is positive for s

Current/ Expected Orderbook/ Pending Orders?

Shaily Engineering Plastics Limited has secured a significant purchase order for 10 million insulin pens per year, to be supplied over the current and next year. The company expects to fulfill about 60-70% of the outstanding orderbook in the current year, with the balance spilling into the following year. The order pipeline for insulin devices is strengthening, with expectations of big orders over the next 1-2 years, especially as some competitors exit emerging markets tenders. The UK business has a strong pipeline with growth expected of 35%-45%; most active projects generate revenue except t

IN US

Sale is live|00:00:00left today

Shaily Engineering Plastics LtdQ2 FY24Consumer Durables

Shaily Engineering Plastics Ltd Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,850P/E: 89.5Market Cap: ₹12.7K CrSector: Consumer Durables

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Healthcare segment expects strong volume growth, particularly from Q2 FY25 onwards, following resolution of Q1 technical issues.
→Anticipated revenue growth in Healthcare projected at 20%+ for FY25; consolidated growth driven by Healthcare expansion.
→New contracts and projects in Healthcare (e.g., Lanreotide, Semaglutide) expected to contribute revenues in coming quarters.
→Own IP insulin pen injector order for 10 million units per year indicates scaling opportunity; additional large insulin orders likely in next 1-2 years.
→UK business projected to grow 35-45%, with continued development projects fueling revenue.
→Consumer and Industrial segments expected to grow, with new projects in home furnishing and automotive components ramping up by Q2-Q3 FY25.
→Capacity expansions planned over next 18-24 months to meet growing demand, including doubling pen platform capacities.
→Overall focus on scaling business significantly over next 5 years with increased own IP product contribution.

Margin guidance

Category 3

→Shaily Engineering Plastics Limited delivered a robust 14% revenue growth in Q1 FY25 and improved EBITDA margins to 20.1%.
→The Healthcare segment revenue grew 21%, with strong order pipelines including new pen injectors and contract manufacturing opportunities.
→UK business expected to grow 35-45%, with profitability increasing alongside scale-up in India operations.
→Purchase orders for 10 million pen injectors for insulin market indicate significant volume growth potential.
→Anticipated doubling of pen platform capacities in the next 18-24 months to meet rising demand.
→Outlook is positive for sustained healthy margins across product lines including GLP-1 and insulin devices.
→Focus on scalable growth, increasing own IP contribution, and expansion into medical devices, specialized packaging, and delivery solutions.
→PAT grew 38% YoY in Q1 FY25, with improved ROCE (20.7%) and ROE (15.6%), indicating strong profitability trajectory.
→Revenue growth expected to accelerate from Q2 FY25, driven by new projects and order executions.

3 more insights locked — sign up free to unlock

Fundraise plans

The transcript does not mention any current or future fundraising plans through debt or equity. Key points related to fundraising: - No specific mention of raising funds via debt or equity in the Q1 FY25 earnings call. - The company emphasizes disciplined use of capital while achieving growth. - Focus is on scaling the business with existing resources, expanding capacities, and increasing revenues. - Plans include capacity expansion over the next 18-24 months but without indicating any related financing. - No discussion about new fundraises or capital raising initiatives was addressed during the Q&A. In summary, there is no indication from the transcript that Shaily Engineering Plastics Limited is planning any current or future fundraising via debt or equity.

Order book

Yes

→Shaily Engineering Plastics Limited has secured a significant purchase order for 10 million insulin pens per year, to be supplied over the current and next year.
→The company expects to fulfill about 60-70% of the outstanding orderbook in the current year, with the balance spilling into the following year.
→The order pipeline for insulin devices is strengthening, with expectations of big orders over the next 1-2 years, especially as some competitors exit emerging markets tenders.
→The UK business has a strong pipeline with growth expected of 35%-45%; most active projects generate revenue except two in early development stages.
→New projects in home furnishings (~Rs. 50 crore), pharma new applicators (~Rs. 35 crore), and knobs (~Rs. 40 crore) were expected to start in Q2 FY25.
→The company is also pursuing orders in consumer electronics and automotive components, with fungible capacity utilization and no major additional investment needed.

Capex plans

Yes

→The company plans to expand some healthcare capacities over the next 18 to 24 months, including doubling up on some pen platforms to meet growing demand.
→No significant additional investment is needed to switch capacities from existing non-healthcare segments to other areas like automotive; only marginal investment in testing equipment or robotic handling may be required.
→The existing drug device capacity is 40 million devices, and the company is targeting to utilize and expand this capacity within the next 18 to 24 months.
→Shaily UK’s profitability is expected to grow alongside Indian manufacturing profitability, contributing to healthier consolidated numbers as scale increases.
→The company is at a very nascent stage in evaluating new opportunities in consumer electronics and will provide updates in due course.

How does Shaily Engineering Plastics Ltd rank vs peers in Consumer Durables?

Pro feature

1Shaily Engineering Plastics Ltd

Rev 3Mar 3

See full Consumer Durables sector rankings

Want more stocks like Shaily Engineering Plastics Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio